---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Incidence"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Incidence. Topics: United States: claims-based incidence, 2023; United States: Olmsted County, Minnesota, population-based incidence, 1982 to 2001; Global pooled incidence: systematic review and meta-analysis; South Korea: nationwide claims-based incidence, 2016 to 2020; 1 further topic. 5 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/incidence"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of Chronic inflammatory demyelinating polyneuropathy

<a id="topic-2.2.1.2.1-1"></a>

### United States: claims-based incidence, 2023

> “After adjusting for age and sex and extrapolating to the US population, the estimated incidence rate was 2.8 (95% CI 2.7–2.9) per 100,000 persons or approximately 9,238 patients diagnosed with CIDP in 2023.”
> “corresponding to a raw incidence rate of 2.2 (95% CI 2.0–2.3) per 100,000 persons in 2023”
> “Patients were identified as having CIDP if they had 2 or more claims containing ICD-10 codes for CIDP (G61.81) separated by 30 or more days”
> “In this analysis, the incidence estimate decreased and prevalence estimate increased compared to our 2019 analysis, for which we calculated an adjusted incidence rate of 3.6 per 100,000 persons per year”

Source: [Gable et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880827/)

<a id="topic-2.2.1.2.1-2"></a>

### United States: Olmsted County, Minnesota, population-based incidence, 1982 to 2001

> “To determine the incidence (1982–2001) and prevalence (on January 1, 2000) of CIDP in Olmsted County, Minnesota, and whether DM is more frequent in CIDP.”
> “The incidence of CIDP was 1.6/100,000/year.”

Source: [Laughlin et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2707109/)

<a id="topic-2.2.1.2.1-3"></a>

### Global pooled incidence: systematic review and meta-analysis

> “The pooled crude incidence rate was 0.33 per 100,000 person-years (95% CI 0.21–0.53; I2 = 95.7%)”
> “Crude incidence rates varied between 0.15 and 0.70 cases per 100,000 person-years”
> “The pooled crude incidence rate for studies using the AAN criteria is 0.36 per 100,000 person-years (95% CI 0.30–0.44, I2 = 0.0%; prediction interval 0.30–0.44).”
> “In general, the reported crude incidence rates were higher in males than females (gender rate ratios varied between 1.5 and 4.0; Table 3).”

Source: [Broers et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6518865/)

<a id="topic-2.2.1.2.1-4"></a>

### South Korea: nationwide claims-based incidence, 2016 to 2020

> “The age-adjusted incidence rates were 0.22, 0.21, 0.23, 0.30, and 0.25 per 100,000 person-years in 2016, 2017, 2018, 2019, and 2020, respectively.”

Source: [Jung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10622719/)

<a id="topic-2.2.1.2.1-5"></a>

### Iceland: population-based incidence, 1991 to 2011

> “The average annual incidence was 0.3/100,000 (95% CI 0.04-2.47).”

Source: [Hafsteinsdottir and Olafsson (2016)](https://pubmed.ncbi.nlm.nih.gov/27211228/)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
